Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma in Non Small Cell Lung Cancer

Terminated

Conditions: Non Small Cell Lung Carcinoma

Registration Number: NCT02762877

Lead Sponsor: Genomic Health®, Inc.

Brief Summary: A study to determine the concordance of key actionable genomic alterations as assessed in tumor tissue and plasma from patients with non small cell lung carcinoma (NSCLC)

Detailed Description: This is a prospective clinical study to characterize the concordance of key clinically relevant genomic alterations in tumor tissue (biopsy/excision/cytology) and liquid biopsy (blood) using the Genomic Health LBMP in patients with stage IV non squamous NSCLC, that are either newly diagnosed with metastatic disease or progressing on therapy (any line). Tissue biopsy and blood collection (liquid biopsy) should be less than eight weeks apart and with no new systemic antitumoral treatment given in the interval between the tissue biopsy and blood collection. Local assessment of tumor tissue samples will be performed at each participating institution as per their clinical standard of care practices and results from the local assessment of genomic alteration status will be used.

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 140

Inclusion Criteria

Subjects must be 18 years or older.
Patients with stage IV non squamous NSCLC who are either newly diagnosed or progressing on any treatment (progression defined as increasing tumor size or new metastatic lesions on clinical or imaging assessment).
Patients with available tissue sample from a metastatic site or, if the patient presents with stage IV disease at diagnosis, from the primary tumor or a metastatic site. If a patient is progressing on EGFR targeted therapy (erlotinib, gefitinib, afatinib), tumor tissue sample is required only if available.
No new systemic anti-tumor therapy administered in the interval between the tissue biopsy and collection of the blood sample. (interval not to exceed eight weeks). Local radiation therapy is permitted.
Able and willing to read, understand and sign an informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization, or equivalent privacy law, where this is applicable.

Exclusion Criteria

Patients who are currently receiving therapy (targeted, immune- or chemotherapy) without sign of progression.
Patients with squamous NSCLC.
Patients with more than 8 weeks between collection of tumor specimen and collection of blood sample for analysis. (Not applicable for patients progressing on EGFR targeted therapy with no biopsy at progression)
Patients changing EGFR therapy due to toxicity or preference without documented disease progression.
Patients progressing on Osimertinib treatment.
Patients with brain metastases only.
Inability to comply with study and/or follow-up procedures.
Unable or unwilling to provide written informed consent.

Study & Design

Study Type: OBSERVATIONAL

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Concordance of Genomic Alterations in EGFR Detected in Plasma Versus Tumor Tissue in Stage IV Non Squamous NSCLC Patients Who Are Newly Diagnosed or Progressing on Treatment	Time between patient tumor tissue biopsy and and blood collection, up to 8 weeks	Assess concordance of genomic alterations in EGFR detected in plasma (using the OncotypeSEQ Liquid Select assay) versus tumor tissue (assessed centrally using FoundationOne, or locally based on the patient's clinic) in stage IV non squamous NSCLC patients who are newly diagnosed or progressing on treatment.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants With EGFR T790M Alterations in Plasma in Patients Progressing on EGFR Targeting Therapy (Erlotinib, Gefitinib, Afatinib).	Time between patient tumor tissue biopsy and and blood collection (blood collected after the patient progressed on EGFR targeted therapy)	Detection of EGFR T790M alterations in plasma using the OncotypeSEQ Liquid Select assay. Progression on EGFR targeting therapy (erlotinib, gefitinib, afatinib) assessed clinically or radiologically
Concordance of Genomic Alterations in ALK (EML4-ALK Fusions) Detected in Plasma Versus Tumor Tissue.	Time between patient tumor tissue biopsy and and blood collection, up to 8 weeks	Assess concordance of genomic alterations in ALK (EML4-ALK fusions) detected in plasma (using the OncotypeSEQ Liquid Select assay) versus tumor tissue (assessed centrally using FoundationOne OR locally based on the patient's clinic) in stage IV non squamous NSCLC patients who are newly diagnosed or progressing on treatment.

Trial Locations

Locations (22): Cancer Care Associates d/b/a Torrance Memorial Physician Network
🇺🇸
Torrance, California, United States
Central Georgia Cancer Care
🇺🇸
Macon, Georgia, United States
Bon Secours Cancer Institute
🇺🇸
Midlothian, Virginia, United States
Fundación Arturo López Perez
🇨🇱
Santiago, Chile
Tokyo Medical University Hospital
🇯🇵
Tokyo, Shinjuku-ku, Japan
Centre Jean Perrin
🇫🇷
Clermont-Ferrand, Cedex 1, France
Clatterbridge Cancer Center NHS Foundation Trust
🇬🇧
Bebington, Wirral, United Kingdom
West Clinic
🇺🇸
Germantown, Tennessee, United States
Hospital Universitario Central Asturias
🇪🇸
Oviedo, Spain
Gabrail Cancer Center
🇺🇸
Canton, Ohio, United States
Clinica Alemana de Santiago
🇨🇱
Santiago, Chile
Hospital Universitario Virgen del Rocio
🇪🇸
Sevilla, Spain
Hospital Clinico Universitario Lozano Blesa
🇪🇸
Zaragosa, Spain
Essex Oncology of North Jersey
🇺🇸
Belleville, New Jersey, United States
Meridian Hospitals
🇺🇸
Neptune, New Jersey, United States
Hôpital Nord
🇫🇷
Marseille, Cedex 20, France
Polyclinique Bordeaux Nord Aquitaine
🇫🇷
Bordeaux, France
St. Vincent's University Hospital
🇮🇪
Dublin, Elm Park, Ireland
Virginia Piper Cancer Institute
🇺🇸
Minneapolis, Minnesota, United States
Instituto Nacional del Torax
🇨🇱
Santiago, Chile
National Cancer Center
🇯🇵
Tokyo, Tsukiji, Chuo-ku, Japan
MultiCare Health System
🇺🇸
Tacoma, Washington, United States